SCHEDULE 13G/A: BlackRock Discloses 1.8% Passive Stake in Shattuck Labs

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 1.8% of Shattuck Labs, Inc.'s common stock as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 878,754 shares of Shattuck Labs, Inc. common stock.
• This represents 1.8% of the total class of securities.
• BlackRock holds sole voting power over 871,750 shares and sole dispositive power over 878,754 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Shattuck Labs, Inc.
• The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934.

Sentiment

Score: 7

Explanation: The filing indicates a significant institutional investor, BlackRock, maintains a passive stake in Shattuck Labs, Inc., which can be viewed positively as a vote of confidence in the company's long-term value and stability.

Positives

• The disclosure of BlackRock, a major institutional investor, holding a stake in Shattuck Labs, Inc. can be viewed as a vote of confidence in the company's long-term prospects.
• The passive nature of the investment indicates BlackRock is not seeking to influence control, suggesting a belief in current management and strategy.

Risks

• The document does not detail specific risks related to Shattuck Labs, Inc.'s operations or financial health, as it is a disclosure of ownership.
• The primary risk related to this filing is the potential for future changes in BlackRock's ownership, which could impact market perception.

Future Outlook

This filing reports past ownership as of a specific date and does not provide any forward-looking statements or guidance regarding Shattuck Labs, Inc.'s future performance or BlackRock's investment strategy.

Industry Context

This Schedule 13G filing indicates a significant institutional investor, BlackRock, holds a passive stake in Shattuck Labs, Inc. Such filings are routine disclosures for large investment firms that acquire more than 5% of a company's stock (or amend a previous filing) but do not intend to influence control. It signals BlackRock's presence as a shareholder, which is common for publicly traded companies, especially those in the biotechnology or pharmaceutical sectors like Shattuck Labs, Inc., where institutional investment is prevalent.

Comparison to Industry Standards

• BlackRock's 1.8% stake in Shattuck Labs, Inc. is a standard passive investment for a large asset manager, falling below the 5% threshold that typically triggers an initial Schedule 13G filing.
• Institutional ownership is common across the biotechnology and pharmaceutical industries, with major firms like Vanguard, State Street, and Fidelity often holding similar passive stakes in numerous companies.
• For example, a company like Moderna (MRNA) or BioNTech (BNTX) would typically have significant institutional ownership from these same large asset managers, often exceeding 5% for individual funds or the aggregate for the entire firm, demonstrating a common investment pattern for such entities.

Stakeholder Impact

• Shareholders: The presence of a large, passive institutional investor like BlackRock can provide a degree of stability and legitimacy to the shareholder base.
• Management: BlackRock's passive stance suggests they are not seeking to influence management or corporate strategy, allowing current leadership to continue their plans.

Key Dates

Keywords

BlackRock, Shattuck Labs, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Equity Stake